MAIA Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 13
- Market Cap
- $66.9M
- Website
- http://maiabiotech.com
- Introduction
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
- Conditions
- Carcinoma, Non-Small -Cell Lung
- Interventions
- Drug: 6-Thio-2'-Deoxyguanosine
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Maia Biotechnology
- Target Recruit Count
- 300
- Registration Number
- NCT06908304
THIO Sequenced With Cemiplimab in Advanced NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: 6-Thio-2'-Deoxyguanosine
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Maia Biotechnology
- Target Recruit Count
- 227
- Registration Number
- NCT05208944
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan
🇨🇳Tri-Service General Hospital, Taipei City, Neihu District, Taiwan
🇨🇳Chang-Gung Memorial Hospital, Kaohsiung, Niaosong District, Taiwan
News
MAIA Biotechnology Expands Scientific Advisory Board with HCC Experts as Phase 2 Trial Approaches
MAIA Biotechnology appointed two prominent hepatocellular carcinoma specialists, Dr. Claudia Fulgenzi and Dr. David J. Pinato, to its Scientific Advisory Board to guide upcoming clinical trials.
THIO Plus Cemiplimab Demonstrates Promising Activity in ICI-Resistant Advanced NSCLC
The combination of THIO (ateganosine) plus cemiplimab showed clinical activity with a 77% disease control rate in patients with advanced NSCLC resistant to immune checkpoint inhibitors.
MAIA Biotechnology Raises $695,000 in Private Placement to Fund Phase II THIO-101 Cancer Trial
MAIA Biotechnology completed a $695,000 private placement offering 463,332 shares and warrants to fund its Phase II THIO-101 cancer trial.
MAIA Biotechnology's Novel Cancer Drug Ateganosine Receives USAN Approval for NSCLC Treatment
MAIA Biotechnology has secured USAN Council approval for "ateganosine" as the nonproprietary name for its lead anticancer agent THIO, marking a crucial regulatory milestone.
Frontline Therapy for Transplant-Ineligible Multiple Myeloma: Evolving Treatment Approaches
Recent trials like PERSEUS and CASSIOPEIA have significantly transformed the approach to frontline therapy for transplant-ineligible multiple myeloma patients.
MAIA Biotechnology's THIO Shows Promise in Phase II Lung Cancer Trial; Institutional Investment Increases
MAIA Biotechnology's lead candidate, THIO, is currently in Phase II clinical trials, evaluating its potential in treating patients with non-small cell lung cancer.
MAIA Biotechnology Advances THIO to Phase 3 for Advanced NSCLC
MAIA Biotechnology plans to initiate the THIO-104 Phase 3 trial in 2025 to assess THIO in non-small cell lung cancer (NSCLC) patients resistant to checkpoint inhibitors.
MAIA Biotechnology and BeiGene Collaborate to Evaluate THIO in Multiple Cancers
MAIA Biotechnology and BeiGene enter a clinical supply agreement to assess THIO, combined with tislelizumab, in Phase 2 trials.
MAIA Biotechnology Expands THIO-101 Trial Following Positive Interim Results; Directors Increase Stock Holdings
• MAIA Biotechnology's Phase 2 THIO-101 trial, evaluating THIO with Regeneron's Libtayo® for third-line NSCLC, is expanding due to promising interim results. • Interim data from the THIO-101 trial showed a median survival follow-up of 10.6 months, compared favorably to the 5.8-month standard-of-care overall survival. • MAIA Biotechnology directors Ramiro Guerrero and Stan Smith recently increased their investment in the company through stock and warrant purchases. • The company is considering an accelerated approval pathway in the United States based on the THIO-101 trial outcomes.
MAIA Biotechnology Secures Funding to Advance THIO Clinical Trials
MAIA Biotechnology has announced a private placement of common stock and warrants, expected to generate approximately $950,000 in gross proceeds.